|Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains|
|Wang, Li-Hui; Cheng, Hong; Hu, Fu-Lian; Li, Jiang|
|关键词||Helicobacter pylori Antibiotic resistance Quinolones Mutation gyrA|
|刊名||WORLD JOURNAL OF GASTROENTEROLOGY|
|WOS标题词||Science & Technology|
|类目[WOS]||Gastroenterology & Hepatology|
|研究领域[WOS]||Gastroenterology & Hepatology|
|关键词[WOS]||ESCHERICHIA-COLI ; CONSENSUS REPORT ; TRIPLE THERAPY ; ERADICATION ; INFECTION ; LEVOFLOXACIN ; MOXIFLOXACIN ; PREVALENCE ; MANAGEMENT ; EFFICACY|
AIM: To investigate the resistance of Helicobacter pylori (H. pylon) to ciprofloxacin (CIP), levofloxacin (LVX) and moxifloxacin (MOX) in the Beijing area and to elucidate the resistance mechanisms.
METHODS: Seventy-nine H. pylori clinical strains, isolated from patients who had undergone upper gastrointestinal endoscopy in Peking University First Hospital from 2007 to 2009, were tested for their susceptibility to CIF, LVX and MOX using the if-test method. H. pylori strain 26695 was included in the susceptibility testing as a control strain. According to the minimal inhibitory concentration (MIC) values, a strain was classified as resistant to CIP, LVX or MOX when the MIC was > 1 mu g/mL. We amplified by polymerase chain reaction (PCR) and sequenced the quinolone resistance-determining regions of the gyrA and gyrB genes from 29 quinolone-resistant and 16 quinolone-susceptible H. pylori strains selected at random.
RESULTS: In this study, the resistance rates of H. pylon to CIP, LVX or MOX were 55.7% (44/79), and the primary resistance rates were 26.6% (21/79). Patients with secondary resistance had received LVX in previous eradication treatments, but not MOX or CIP. Forty-five strains, including 29 CIP, LVX or MOX-resistant strains (MIC: 1.5-32 mu g/mL) and 16 susceptible strains, were selected randomly from the 79 strains and used in PCR analysis. Among these 45 strains, 27 resistant strains had mutations in the gyrA gene, including 11 strains with mutations corresponding to Asp-91 (MIC: 2-32 mu g/mL), one of which also had a mutation corresponding to Val-150, and 16 strains had mutations at Asn-87 (MIC: 4-32 mu g/mL), three of which also had mutations corresponding to Arg-140 or Val-150. In addition, Arg-140, Val-150 or Ala-97 mutations were separately detected in three susceptible strains. Analysis of the gyrB gene showed that one strain of low resistance had a mutation corresponding to Ser-457 that coexisted with an Asp-91 mutation. There was a significant difference in the occurrence of mutations in the gyrA gene between CIP, LVX and MOX-resistant and -susceptible strains (P < 0.05), but 2 resistant strains were found to possess no quinolone resistance-determining region mutations.
CONCLUSION: Resistance is primarily mediated through point mutations in gyrA. Whether other mechanisms are responsible for resistance in strains without mutations in the QRDR should be detected. (C) 2010 Baishideng. All rights reserved.
|资助机构||Beijing Medicine Research and Development Fund|
|作者单位||Peking Univ First Hosp, Dept Gastroenterol, Beijing 100034, Peoples R China|
|Wang, Li-Hui,Cheng, Hong,Hu, Fu-Lian,et al. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains[J]. WORLD JOURNAL OF GASTROENTEROLOGY,2010,16(18):2272-2277.|
|APA||Wang, Li-Hui,Cheng, Hong,Hu, Fu-Lian,&Li, Jiang.(2010).Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains.WORLD JOURNAL OF GASTROENTEROLOGY,16(18),2272-2277.|
|MLA||Wang, Li-Hui,et al."Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains".WORLD JOURNAL OF GASTROENTEROLOGY 16.18(2010):2272-2277.|